Save up -80% on Ustekinumab
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Stelara
|$20,489||1 syringe (1ml) 90 mg/ml|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Ustekinumab coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Ustekinumab every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Ustekinumab volume of distribution
Plaque psoriasis and psoriatic arthritis dosing: 45mg: ~0.161L/kg 90mg: ~0.179L/kg
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Ustekinumab
Ustekinumab, is a human immunosuppressive drug developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23. Since 2009, ustekinumab has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. In September 2016, Janssen announced that the FDA approved the medication for the treatment of moderate-severe Crohn’s disease.
Ustekinumab mechanism of action
Ustekinumab is a human IgG1-kappa monoclonal antibody designed to interfere with the triggering of the body’s inflammatory response through the suppression of certain cytokines. Specifically, ustekinumab blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit of IL-12 and IL-23, therefore disrupting the proinflammatory pathway that contributes to several chronic diseases. In a more minor role, ustekinumab also interferes with the expression of monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF- ), interferon-inducible protein-10 (IP-10), and interleukin IL-8.
Dosage forms of Ustekinumab
|Injection, solution||subcutaneous||45 mg/.5mL|
|Injection, solution||subcutaneous||90 mg/mL|
Humans and other mammals
Indication of Ustekinumab
Ustekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn’s disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn’s disease.
Toxicity of Ustekinumab
No dose-related or cumulative toxicity was observed with increasing duration of ustekinumab exposure for up to 5 years. Rates of AEs reported in ustekinumab psoriasis trials are generally comparable with those reported for other biologics approved for the treatment of moderate-to-severe psoriasis.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Ustekinumab on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.